News

HKU-CTC set up a Chinese New Year Booth at Queen Mary Hospital on 21st January, 2020, to celebrate Chinese New Year with the supporters. Dr. Hong, one of the CTC Panda Ambassadors, visited the booth on that day. He gave out calendar cards and fai-chuns to the visitors. Visitors who participated in the quiz game at the booth and answered all questions correctly were given specially designed red packets as well. The responses were enthusiastic. Here are some highlights of the event:

Novel coronavirus emerges in Hong Kong recently. Dr. Hong, Panda Ambassador of HKU Clinical Trials Centre, also wears a face mask to protect himself from viruses!

He wants to take this chance to remind you all to stay healthy and maintain personal hygiene to stop the spread of virus and avoid being infected. Dr. Hong is introducing you some useful tips:-

The investigational drug of this study is EXPAREL^®, a local anesthetic, which was approved by the US Food and Drug Administration (FDA) in 2011 on postsurgical pain relief. HKU-CTC was delegated to perform this study to evaluate the metabolic and safety profiles of this drug in Chinese population.

Recruitment of this study started in October 2019, and 20 healthy volunteers were recruited. The duration of this clinical study was around 54 days, including screening, 6-night confinement, ambulatory visits and a follow up phone call. During the study period, volunteers received one dose of the investigational drug via subcutaneous injection at multiple points. Due to the long staying period, HKU-CTC organized 3 workshops for the healthy volunteers, including Turkish Mosaic Lamp Workshop, Little Paper Art Night Lamp Workshop and Art of Paper Tearing Workshop. The project was completed in January 2020.

The ICN Annual Steering Board Meeting 2019 took place on September 26, 2019 in Freiburg, Germany and was hosted by Clinical Trials Unit Freiburg of University Hospital Freiburg, one of the founding members. During the meeting, all steering board members reported their recent activities, and together formulated an action plan for the coming year through intensive small group discussions and open exchange of ideas over panel meetings. Mr. Henry Yau, Managing Director of HKU-CTC, was elected the new ICN Vice-Chairperson and will work together with the new Chairperson, Dr. Thomas Hiemstra of Cambridge Clinical Trials Unit and other Steering Board members to contribute to ICN’s exciting development in the coming two years.

The ICN Symposium 2019 was held following the Steering Board Meeting. Twelve speakers from Germany, United Kingdom, Switzerland, Sweden, Turkey, Taiwan and Hong Kong shared their insightful ideas around the theme of “Clinical Trials in the Global and Digital World”. Mr. Henry Yau, our Managing Director, and Dr. Creany Wong, our Associate Director, shared their experience on “clinical trials central management and digitalization” and received enthusiastic responses from the floor.

The next ICN Steering Board Meeting and Symposium will be hosted by HKU-CTC in November 2020 in Hong Kong.

When most people think of medical careers, the life of a practicing doctor immediately come to mind. However, there is also a very different option in the medical field which involves an alternative pathway: be a medical researcher.

30 students who are newly admitted to the HKU Bachelor of Medicine and Bachelor of Surgery Programme (MBBS) this year visited HKU Phase 1 Clinical Trials Centre on July 8, 2019. An information session introducing the concepts of clinical research was delivered by Dr. Creany Wong, Associate Director of HKU-CTC, followed by a tour around the Centre.

The students reflected that it was an eye-opening experience as they had never thought of the possibility of entering the research field after the completion of a medical degree. Some considered that it could also be another way to contribute to the society and to the betterment of mankind.

The investigational drug, Benralizumab, is a novel drug for treating asthma. It was approved in USA, European Union, Japan and Canada. HKU Clinical Trials Centre conducted the phase 1 clinical research of the drug to evaluate the metabolism and safety of the drug using different doses in Chinese population.

Recruitment started in March 2019 and 36 healthy volunteers were selected to join the study. The whole study took 17 weeks and it included screening, 3-day-2-night confinement and follow-up visits. Volunteers were divided into 2 groups to receive injection. The research was completed in August 2019. 

Available in Chinese only

(Available in Chinese only)

(Available in Chinese only)

(Available in Chinese only)